• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利:CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法,用中文像聊天一样搜索,搜遍4000万医学文献。AI智能推荐,让科研检索更轻松。

立即免费搜索

文件翻译

保留排版,准确专业,支持PDF/Word/PPT等文件格式,支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述,25分钟生成高质量综述,智能提取关键信息,辅助科研写作。

立即免费体验

越南人群家族性高胆固醇血症中低密度脂蛋白受体(LDLR)与载脂蛋白B(APOB)相互作用的探索:一种蛋白质-蛋白质对接方法。

Exploring LDLR-APOB Interactions in Familial Hypercholesterolemia in the Vietnamese Population: A Protein-Protein Docking Approach.

作者信息

Kim Ngoc-Thanh, Do Doan-Loi, Nguyen Mai-Ngoc Thi, Le Hong-An, Le Thanh-Tung, Truong Thanh-Huong

机构信息

Department of Cardiology, Hanoi Medical University, Hanoi, Vietnam.

Vietnam National Heart Institute, Bach Mai Hospital, Hanoi, Vietnam.

出版信息

Bioinform Biol Insights. 2024 Nov 28;18:11779322241301267. doi: 10.1177/11779322241301267. eCollection 2024.

DOI:10.1177/11779322241301267
PMID:39619738
原文链接:https://pmc.ncbi.nlm.nih.gov/articles/PMC11605763/
Abstract

Atherosclerotic cardiovascular diseases (CVDs) are closely linked to factors such as familial hypercholesterolemia (FH), often caused by mutations in low-density lipoprotein receptor () and apolipoprotein B (). Through a comprehensive bioinformatic analysis, we identified novel and mutations and their cardiovascular disease (CVD) implications, focusing on unique variants in the Vietnamese population. We used homology modeling to predict protein structures; in addition, through protein-protein molecular docking, we assessed how these mutations affect binding affinities. We identified 10 novel binding residues exclusive to the wild-type and precursor LDLR isoforms, including ASP-47, GLY-48, and GLU-51. Analyses of 154 complexes revealed 5 isoforms with low binding affinities and notable hydrogen-bonding interactions-APOB (Arg3527Trp)-LDLR (Cys318Arg), APOB (His3583Leu)-LDLR (Cys104Tyr), APOB wild-LDLR (Glu228Lys), APOB (Phe2469Cys)-LDLR (Glu288Lys), and APOB wild-LDLR (Ser130Ter). These results suggest strong and potentially detrimental interactions among these proteins. Furthermore, they highlight the molecular mechanisms underlying CVD development, reveal potential therapeutic targets, enhance our understanding of genetic variations, and could guide FH research.

摘要

动脉粥样硬化性心血管疾病(CVD)与家族性高胆固醇血症(FH)等因素密切相关,FH通常由低密度脂蛋白受体()和载脂蛋白B()的突变引起。通过全面的生物信息学分析,我们确定了新的和突变及其对心血管疾病(CVD)的影响,重点关注越南人群中的独特变异。我们使用同源建模来预测蛋白质结构;此外,通过蛋白质-蛋白质分子对接,我们评估了这些突变如何影响结合亲和力。我们确定了10个野生型和前体LDLR异构体特有的新结合残基,包括ASP-47、GLY-48和GLU-51。对154个复合物的分析揭示了5种具有低结合亲和力和显著氢键相互作用的异构体——APOB(Arg3527Trp)-LDLR(Cys318Arg)、APOB(His3583Leu)-LDLR(Cys104Tyr)、APOB野生型-LDLR(Glu228Lys)、APOB(Phe2469Cys)-LDLR(Glu288Lys)和APOB野生型-LDLR(Ser130Ter)。这些结果表明这些蛋白质之间存在强烈且可能有害的相互作用。此外,它们突出了CVD发展的分子机制,揭示了潜在的治疗靶点,增强了我们对基因变异的理解,并可为FH研究提供指导。

https://cdn.ncbi.nlm.nih.gov/pmc/blobs/2441/11605763/608a8862407a/10.1177_11779322241301267-fig5.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/2441/11605763/ab7ba5e0465f/10.1177_11779322241301267-fig1.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/2441/11605763/ce6549f8cd3e/10.1177_11779322241301267-fig2.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/2441/11605763/27378ca85dfc/10.1177_11779322241301267-fig3.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/2441/11605763/07bdd1aaa60d/10.1177_11779322241301267-fig4.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/2441/11605763/608a8862407a/10.1177_11779322241301267-fig5.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/2441/11605763/ab7ba5e0465f/10.1177_11779322241301267-fig1.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/2441/11605763/ce6549f8cd3e/10.1177_11779322241301267-fig2.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/2441/11605763/27378ca85dfc/10.1177_11779322241301267-fig3.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/2441/11605763/07bdd1aaa60d/10.1177_11779322241301267-fig4.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/2441/11605763/608a8862407a/10.1177_11779322241301267-fig5.jpg

相似文献

1
Exploring LDLR-APOB Interactions in Familial Hypercholesterolemia in the Vietnamese Population: A Protein-Protein Docking Approach.越南人群家族性高胆固醇血症中低密度脂蛋白受体(LDLR)与载脂蛋白B(APOB)相互作用的探索:一种蛋白质-蛋白质对接方法。
Bioinform Biol Insights. 2024 Nov 28;18:11779322241301267. doi: 10.1177/11779322241301267. eCollection 2024.
2
DIAgnosis and Management Of familial hypercholesterolemia in a Nationwide Design (DIAMOND-FH): Prevalence in Switzerland, clinical characteristics and the diagnostic value of clinical scores.在全国范围内设计(DIAMOND-FH)中诊断和管理家族性高胆固醇血症:瑞士的流行情况、临床特征和临床评分的诊断价值。
Atherosclerosis. 2018 Oct;277:282-288. doi: 10.1016/j.atherosclerosis.2018.08.009.
3
Screening and verifying the mutations in the LDLR and APOB genes in a Chinese family with familial hypercholesterolemia.筛查并验证一个中国家族性高胆固醇血症家系中 LDLR 和 APOB 基因的突变。
Lipids Health Dis. 2023 Oct 18;22(1):175. doi: 10.1186/s12944-023-01935-8.
4
LDLR missense variants disturb structural conformation and LDLR activity in T-lymphocytes of Familial hypercholesterolemia patients.载脂蛋白 B100 基因突变干扰家族性高胆固醇血症患者 T 淋巴细胞的结构构象和 LDLR 活性。
Gene. 2023 Feb 15;853:147084. doi: 10.1016/j.gene.2022.147084. Epub 2022 Dec 1.
5
The molecular basis of familial hypercholesterolemia in the Czech Republic: spectrum of LDLR mutations and genotype-phenotype correlations.捷克家族性高胆固醇血症的分子基础:LDLR 突变谱及基因型-表型相关性。
Atherosclerosis. 2012 Aug;223(2):401-8. doi: 10.1016/j.atherosclerosis.2012.05.014. Epub 2012 May 23.
6
Improvement of Definite Diagnosis of Familial Hypercholesterolemia Using an Expanding Genetic Analysis.通过扩展基因分析改善家族性高胆固醇血症的明确诊断
JACC Asia. 2021 Apr 21;1(1):82-89. doi: 10.1016/j.jacasi.2021.04.001. eCollection 2021 Jun.
7
The , , and Variants of Index Patients with Familial Hypercholesterolemia in Russia.俄罗斯家族性高胆固醇血症先证者的 、 和 变异体。
Genes (Basel). 2021 Jan 6;12(1):66. doi: 10.3390/genes12010066.
8
Evidence for a third genetic locus causing familial hypercholesterolemia. A non-LDLR, non-APOB kindred.第三个导致家族性高胆固醇血症的基因位点的证据。一个非低密度脂蛋白受体(LDLR)、非载脂蛋白B(APOB)的家族。
J Lipid Res. 1999 Jun;40(6):1113-22.
9
Familial Hyperlipidemia Caused by Apolipoprotein B Mutation in the Pediatric Amish Population: A Mini Review.儿科阿米什人群中载脂蛋白B突变引起的家族性高脂血症:一篇综述
Interv Cardiol (Lond). 2023;15(Suppl 17):433-437. Epub 2023 Jul 4.
10
Molecular characterization of Iranian patients with possible familial hypercholesterolemia.伊朗可能患有家族性高胆固醇血症患者的分子特征分析
Indian J Clin Biochem. 2011 Jul;26(3):244-8. doi: 10.1007/s12291-011-0113-7. Epub 2011 Feb 10.

本文引用的文献

1
Cholesterol metabolism: physiological regulation and diseases.胆固醇代谢:生理调节与疾病
MedComm (2020). 2024 Feb 24;5(2):e476. doi: 10.1002/mco2.476. eCollection 2024 Feb.
2
Screening and verifying the mutations in the LDLR and APOB genes in a Chinese family with familial hypercholesterolemia.筛查并验证一个中国家族性高胆固醇血症家系中 LDLR 和 APOB 基因的突变。
Lipids Health Dis. 2023 Oct 18;22(1):175. doi: 10.1186/s12944-023-01935-8.
3
Predictive Modeling and Structure Analysis of Genetic Variants in Familial Hypercholesterolemia: Implications for Diagnosis and Protein Interaction Studies.
家族性高胆固醇血症中遗传变异的预测建模和结构分析:对诊断和蛋白质相互作用研究的影响。
Curr Atheroscler Rep. 2023 Nov;25(11):839-859. doi: 10.1007/s11883-023-01154-7. Epub 2023 Oct 17.
4
Genetic and molecular architecture of familial hypercholesterolemia.家族性高胆固醇血症的遗传和分子结构。
J Intern Med. 2023 Feb;293(2):144-165. doi: 10.1111/joim.13577. Epub 2022 Oct 17.
5
Host-microbiome protein-protein interactions capture disease-relevant pathways.宿主-微生物组蛋白质-蛋白质相互作用捕获与疾病相关的途径。
Genome Biol. 2022 Mar 4;23(1):72. doi: 10.1186/s13059-022-02643-9.
6
Binding affinity prediction for protein-ligand complex using deep attention mechanism based on intermolecular interactions.基于分子间相互作用的深度学习注意力机制的蛋白-配体复合物结合亲和力预测。
BMC Bioinformatics. 2021 Nov 8;22(1):542. doi: 10.1186/s12859-021-04466-0.
7
GRaSP: a graph-based residue neighborhood strategy to predict binding sites.GRaSP:一种基于图的残基邻域策略,用于预测结合位点。
Bioinformatics. 2020 Dec 30;36(Suppl_2):i726-i734. doi: 10.1093/bioinformatics/btaa805.
8
Mechanistic Insights into the Oxidized Low-Density Lipoprotein-Induced Atherosclerosis.氧化型低密度脂蛋白诱导动脉粥样硬化的机制研究。
Oxid Med Cell Longev. 2020 Sep 15;2020:5245308. doi: 10.1155/2020/5245308. eCollection 2020.
9
Genetics, Screening, and Treatment of Familial Hypercholesterolemia: Experience Gained From the Implementation of the Vietnam Familial Hypercholesterolemia Registry.家族性高胆固醇血症的遗传学、筛查与治疗:越南家族性高胆固醇血症登记处实施过程中的经验
Front Genet. 2020 Aug 14;11:914. doi: 10.3389/fgene.2020.00914. eCollection 2020.
10
Worldwide Prevalence of Familial Hypercholesterolemia: Meta-Analyses of 11 Million Subjects.全球家族性高胆固醇血症患病率的Meta 分析:1100 万例患者研究
J Am Coll Cardiol. 2020 May 26;75(20):2553-2566. doi: 10.1016/j.jacc.2020.03.057.